tiprankstipranks
Trending News
More News >
Hansa Biopharma AB (SE:HNSA)
:HNSA
Advertisement

Hansa Biopharma AB (HNSA) AI Stock Analysis

Compare
2 Followers

Top Page

SE:HNSA

Hansa Biopharma AB

(HNSA)

Rating:56Neutral
Price Target:
kr33.00
▲(4.56% Upside)
Hansa Biopharma AB's overall stock score is primarily impacted by its financial challenges, which significantly weigh down the score. However, positive technical indicators and a favorable earnings call with strategic initiatives provide some optimism. The valuation remains a concern due to negative earnings.
Positive Factors
Debt Restructuring
The company renegotiated its debt with Novaquest, converting a large portion of it into equity and pushing out cash payments to June 2027.
Reimbursement Approvals
Hansa secured reimbursement for Idefirix in both Australia and Switzerland.
Negative Factors
Regulatory Challenges
Imlifidase only has conditional approval in the EU and no US approval.
Sales Performance
Idefirix’s sales for 2Q25 came below our estimate and the Street consensus, showing 27% QoQ decrease from 1Q25.

Hansa Biopharma AB (HNSA) vs. iShares MSCI Sweden ETF (EWD)

Hansa Biopharma AB Business Overview & Revenue Model

Company DescriptionHansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
How the Company Makes MoneyHansa Biopharma generates revenue through a combination of product sales, licensing agreements, and partnerships with larger pharmaceutical companies. The primary revenue stream comes from the sale of imlifidase, particularly as it gains approval and market access in various regions. Additionally, Hansa Biopharma may engage in collaborative agreements with other biopharmaceutical firms for the development and commercialization of its drug candidates, which can provide upfront payments, milestone payments, and royalties on sales. Strategic partnerships, particularly with companies that have established distribution channels or expertise in the therapeutic areas Hansa targets, also contribute to its financial growth and sustainability.

Hansa Biopharma AB Earnings Call Summary

Earnings Call Date:Jul 17, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong performance in financial metrics and strategic initiatives, such as revenue growth and clinical advancements. However, challenges in Germany and restructuring costs posed some concerns. Despite these difficulties, the company's proactive financial management and market expansion indicate a generally positive outlook.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
IDEFIRIX sales revenue for Q2 2025 was SEK 47.9 million, representing a 76% increase compared to Q2 2024. Total revenue in the first half of 2025 showed a 27% increase compared to the first half of 2024.
Successful Financial Restructuring
The company raised SEK 232 million and restructured existing debt with NovaQuest, ensuring a cash runway into Q2 2026.
Positive Clinical Trial Progress
Completed enrollment of the Phase III PAES study in kidney transplantation and the 15-HMedIdeS-09 Phase II study in Guillain-Barre syndrome delivered positive results.
Operational Cost Savings
Completed restructuring process with expected annual savings of approximately SEK 60 million.
Expansion in Market Access
Secured access in two additional markets, Australia and Switzerland, with IDEFIRIX now reimbursed in 20 countries.
Negative Updates
Challenges in Germany
Germany paused the Euro transplant prioritization program for highly sensitized kidney transplant patients, impacting Q2 revenues and expected to continue affecting near-term performance.
Restructuring Costs
SG&A expenses in Q2 2025 included a SEK 21 million reserve for restructuring actions.
Exchange Rate and Debt Restructuring Impact
Financial income and expenses were impacted by changes in exchange rates and a SEK 59.4 million charge due to the NovaQuest loan restructuring.
Company Guidance
During the Hansa Biopharma second quarter earnings call for 2025, significant guidance was provided on various metrics. The company reported a 76% year-over-year increase in IDEFIRIX sales revenues for Q2 2025, amounting to SEK 47.9 million. For the first half of 2025, IDEFIRIX sales reached SEK 113.5 million, representing a 52% increase compared to the same period in 2024. Total revenues for the first half of 2025 saw a 27% increase from the previous year. The company successfully raised SEK 232 million in capital to support key data readouts in the latter half of 2025 and restructured existing debt with NovaQuest. This restructuring led to a modification of $14.8 million in outstanding debt into equity, with remaining fixed cash payments scheduled from 2027 to 2029. The company's cash runway is now extended into Q2 2026, and operational restructuring is expected to save approximately SEK 60 million annually. Despite a minor unfavorable increase in SG&A expenses, excluding restructuring charges, Hansa's SG&A expenses were 20% favorable compared to the previous year. The operating loss for Q2 2025 was SEK 154.8 million, showing a 17% improvement over Q2 2024.

Hansa Biopharma AB Financial Statement Overview

Summary
Hansa Biopharma AB faces significant financial challenges, with persistent net losses, negative equity, and cash flow difficulties. Despite some revenue growth, high leverage and ongoing operational inefficiencies pose risks to financial stability.
Income Statement
37
Negative
Hansa Biopharma AB's income statement reflects substantial challenges, with consistent net losses and negative EBIT and EBITDA margins. The gross profit margin is relatively higher, indicating some ability to cover variable costs, but the net profit margin remains negative. Revenue has shown some growth over the years, yet profitability remains elusive.
Balance Sheet
22
Negative
The balance sheet indicates significant financial stress with negative stockholders' equity, suggesting more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, while high total debt levels pose a risk. The equity ratio is negative, further highlighting financial instability.
Cash Flow
30
Negative
Cash flow analysis reveals negative operating cash flows and free cash flows, indicating challenges in generating cash from operations. Although financing activities have provided cash inflows, the free cash flow to net income ratio remains unfavorable, reflecting ongoing operational cash deficits.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue196.47M171.32M134.09M154.53M33.88M6.10M
Gross Profit132.81M87.76M70.95M116.05M18.45M5.10M
EBITDA-458.73M-642.07M-714.55M-554.26M-538.83M-413.08M
Net Income-596.17M-807.24M-831.72M-611.13M-548.28M-420.85M
Balance Sheet
Total Assets837.27M800.64M1.02B1.69B1.01B1.43B
Cash, Cash Equivalents and Short-Term Investments354.42M405.28M732.06M1.50B888.96M1.38B
Total Debt906.21M1.08B866.77M791.09M35.38M5.04M
Total Liabilities1.28B1.39B1.19B1.08B255.24M192.37M
Stockholders Equity-441.06M-589.83M-167.88M602.91M757.57M1.24B
Cash Flow
Free Cash Flow-619.84M-675.00M-755.94M-506.06M-483.57M-290.57M
Operating Cash Flow-619.21M-674.88M-755.65M-502.73M-481.17M-290.27M
Investing Cash Flow-628.00K-116.00K-284.00K229.31M-2.40M182.53M
Financing Cash Flow270.50M346.81M-7.54M1.12B-4.86M1.07B

Hansa Biopharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price31.56
Price Trends
50DMA
27.85
Positive
100DMA
26.03
Positive
200DMA
27.71
Positive
Market Momentum
MACD
1.18
Negative
RSI
59.05
Neutral
STOCH
53.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HNSA, the sentiment is Positive. The current price of 31.56 is above the 20-day moving average (MA) of 30.19, above the 50-day MA of 27.85, and above the 200-day MA of 27.71, indicating a bullish trend. The MACD of 1.18 indicates Negative momentum. The RSI at 59.05 is Neutral, neither overbought nor oversold. The STOCH value of 53.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HNSA.

Hansa Biopharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
kr2.70B
20.12%40.54%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
$228.80M-28.70%
€174.93M7.48152.78%
€231.13M-55.23%
€157.17M-41.54%
€56.76M-275.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:HNSA
Hansa Biopharma AB
31.56
-20.39
-39.25%
BOVNF
BioInvent International AB
3.29
-0.22
-6.27%
DE:30S
Saniona AB
1.26
0.93
281.82%
DE:6Y4
Vicore Pharma Holding AB
0.97
-0.36
-27.07%
DE:6XP
Xspray Pharma AB
3.91
-0.48
-10.93%
DE:7V3
Cantargia AB
0.20
-0.12
-37.50%

Hansa Biopharma AB Corporate Events

Hansa Biopharma Announces Extraordinary General Meeting for Board Elections
Aug 7, 2025

Hansa Biopharma AB has announced an Extraordinary General Meeting scheduled for September 2, 2025, to discuss several key resolutions, including the election of new members to the Board of Directors. The Nomination Committee has proposed the election of Elisabeth Björk, Natalie Berner, and Michael Bologna as new board members, with remuneration details outlined for various committee roles. This meeting is significant for the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Reports Positive Trial Results for Imlifidase in DMD Gene Therapy
Aug 1, 2025

Hansa Biopharma has announced promising results from a trial involving the use of imlifidase in patients with Duchenne muscular dystrophy (DMD) prior to gene therapy. The trial showed that imlifidase effectively reduced IgG antibodies, allowing patients to receive Sarepta’s gene therapy, ELEVIDYS. This development could potentially enhance access to gene therapy for patients with high levels of anti-AAV antibodies, positioning Hansa Biopharma as a key player in addressing barriers to gene therapy in rare diseases.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Strengthens Leadership Team with Key Appointments
Jul 29, 2025

Hansa Biopharma announced key executive appointments to bolster its growth and enhance expertise in legal, human resources, and corporate affairs. Brian Gorman, Sandra Frithiof, and Kerstin Falck Lagercrantz join the company in pivotal roles, bringing extensive experience to support Hansa’s strategic initiatives, particularly as it prepares for US pre-commercial activities. These appointments are expected to strengthen Hansa’s operational capabilities and industry positioning, potentially impacting stakeholders positively as the company advances its Phase 3 readouts and BLA submission.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Strengthens Financial Position and Leadership Amidst Strong Sales Growth
Jul 17, 2025

Hansa Biopharma announced a successful capital raise of approximately 232 MSEK/US $24.3M and restructured its debt with NovaQuest, which will support upcoming Phase 3 trial readouts. The company’s IDEFIRIX product sales increased by 76% compared to the previous year, highlighting strong market performance. Additionally, Hansa appointed Maria Törnsén as COO and President U.S., and Dr. Richard Philipson as Chief Medical Officer, strengthening its leadership team. The company remains on track with its clinical pipeline, including a pivotal Phase 3 trial in kidney transplantation and trials in Guillain Barré Syndrome and Duchenne Muscular Dystrophy.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Appoints New Chief Medical Officer
Jul 8, 2025

Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer, effective July 14, 2025. Dr. Philipson brings over 25 years of experience in drug development, particularly in rare diseases and gene therapy, and will play a crucial role in advancing Hansa’s development programs and regulatory submissions. His expertise is expected to enhance the company’s strategic development plans and strengthen its position in the biopharmaceutical industry.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma to Release Q2 2025 Interim Results and Host Conference Call
Jul 3, 2025

Hansa Biopharma announced it will release its interim report for the first half of 2025 on July 17, 2025, followed by a conference call to discuss the results and provide a business and pipeline update. This event, featuring key company executives, is an opportunity for stakeholders to gain insights into Hansa’s operational progress and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Reports Positive Five-Year Outcomes for Imlifidase in Kidney Transplantation
Jun 30, 2025

Hansa Biopharma has presented positive five-year follow-up results from its study on imlifidase in kidney transplantation at the ESOT Congress 2025. The study demonstrated sustained positive outcomes, with a 90% patient survival rate and 82% graft survival rate, indicating that imlifidase is a viable option for highly sensitized patients, providing long-term benefits comparable to standard kidney transplants.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK143.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Expands Share Capital and Voting Rights
Jun 30, 2025

Hansa Biopharma has announced an increase in its registered share capital and number of shares and votes, following the issuance of new ordinary shares and a set-off issue. This development raises the company’s total number of registered shares and votes to 84,763,222, reflecting a strengthened capital position that could enhance its operational capabilities and market presence.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma AB’s AGM Approves Key Resolutions and Incentive Program
Jun 25, 2025

Hansa Biopharma AB held its Annual General Meeting where several key resolutions were passed, including the adoption of financial statements, re-election of board members, and approval of a long-term incentive program for employees. The meeting also authorized the board to issue new shares and warrants, providing the company with financial flexibility to pursue strategic opportunities and enhance shareholder value.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Raises SEK 232 Million and Restructures Debt to Support Growth
Jun 18, 2025

Hansa Biopharma has successfully completed a directed cash share issue, raising approximately SEK 232 million, and has restructured its debt agreement with NovaQuest. This financial maneuver aims to support the company’s ongoing phase III trials for imlifidase and other pipeline projects, positioning Hansa for sustainable growth and strengthening its shareholder base. The restructuring of the NovaQuest agreement includes a set-off issue of USD 14.9 million in new shares and revised payment terms, which are expected to enhance the company’s financial flexibility and operational stability.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Announces Directed Share Issue and Debt Restructuring
Jun 18, 2025

Hansa Biopharma AB has announced a directed share issue of approximately 10 million common shares to institutional investors, with the proceeds intended for general corporate purposes, including ongoing phase III trials for imlifidase and supporting its European business operations. Additionally, the company is restructuring its debt with NovaQuest, which includes a set-off of USD 14.9 million of debt in exchange for new shares, and revised payment terms extending mandatory cash payments until June 2027. This strategic financial maneuver aims to strengthen Hansa’s capital structure and enhance its operational capabilities, positioning the company for continued growth and stability in the competitive biopharmaceutical industry.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma’s CEO to Speak at BIO International Convention
Jun 11, 2025

Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will speak at the BIO International Convention in Boston, focusing on unlocking investment opportunities in European biotech. This participation highlights Hansa’s strategic efforts to engage with potential investors and stakeholders, potentially enhancing its industry positioning and expanding its market reach.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma to Host Virtual Investor Event on Guillain-Barré Syndrome
Jun 9, 2025

Hansa Biopharma announced a virtual investor event on Guillain-Barré syndrome (GBS) scheduled for June 16, 2025. The event will feature presentations from renowned medical professionals discussing the current treatment landscape and scientific advancements in GBS. Company executives will also outline Hansa’s activities and milestones in the autoimmune space. This event is part of a series aimed at the investor community, focusing on Hansa’s key areas of interest: Autoimmune, Gene Therapy, and Kidney Transplantation.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Announces Strategic Restructuring for Enhanced Efficiency
May 26, 2025

Hansa Biopharma AB announced a restructuring plan aimed at optimizing resource allocation and improving operational efficiency, which includes a 20% workforce reduction. This strategic move is expected to save 40-50 MSEK annually and enhance the company’s ability to deliver value to shareholders and patients, pending negotiations with trade unions.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Announces Annual General Meeting for June 2025
May 26, 2025

Hansa Biopharma AB has announced its Annual General Meeting scheduled for June 25, 2025, in Lund, Sweden. The meeting will cover various agenda items including the presentation of financial statements, election of board members, and proposals for a long-term incentive program. This meeting is crucial for stakeholders as it will address key corporate governance issues and strategic decisions that could impact the company’s future direction and market positioning.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma’s Imlifidase Shows Promise in Treating Guillain-Barré Syndrome
May 14, 2025

Hansa Biopharma presented promising data from its Phase 2 study of imlifidase at the 2025 PNS Annual Meeting, highlighting its potential in treating Guillain-Barré Syndrome (GBS). The study demonstrated that imlifidase, when used with standard intravenous immunoglobulin, was safe and well-tolerated, offering significant insights into improving patient care for GBS, a condition with limited treatment options.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Hansa Biopharma Appoints New COO and President U.S.
May 13, 2025

Hansa Biopharma has appointed Maria Törnsén as Chief Operating Officer and President U.S., effective May 19, 2025. With over 20 years of experience in global and U.S. operations, Törnsén’s expertise in rare diseases and gene therapy is expected to drive the company’s growth and profitability, particularly in the U.S. market. Her appointment comes as Hansa prepares for the next phase of development, including the growth of its IDEFIRIX product and anticipated catalysts in late 2025.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025